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In isolated guinea pig perfused hearts ICI 118.551, a selective beta 2 adrenoceptor
antagonist, induced transient ventricular extrasystoles. Following the termination of the perfusion,
a very significant increase of both the ventricular fibrillation threshold and the refractory periods
were measured. In guanethidine pretreated hearts, ICI 118.551 failed to induce premature beats.
At the same time the fibrillation threshold and refractory periods exhibited a very significant
decrease. The perfusion of equimolecular concentration of metoprolol, a beta-1-adrenoceptor
antagonist, and (+) propranolol, a quinidine-like compound, induced, in most experimental
settings, similar results as ICI 118.551. Thus, besides its beta-2-adrenoceptor antagonist
properties, ICI 118.551 presented other pharmacological actions.
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Previously in anesthetized intact rats we have shown that the
intracerebroventricular (icv) injection of sodium glutamate induced cardiac arrhythmias.
We further demonstrated that glutamate induced centrogenic arrhythmias involved a
release of acetylcholine from supraspinal structures, followed by a release of
norepinephrine and an activation of central beta 1 adrenoceptors. Indeed, selective
beta 1 adrenoceptor antagonists, such as practolol, metoprolol, acebutolol prevented
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these arrhythmias, while buthoxamine, a relatively selective beta 2 adrenoceptor
antagonist remained inactive [1, 2, 3].
ICI 118.551 (erythro-DL-1-(7-Methylindan-4-yloxi)-3-isopropylamino-2 butanol
hydrochloride) is a selective beta 2 adrenergic blocking agent [4, 5, 6]. The possible
therapeutic applications of the compound are restricted to glaucoma [7] and muscular
tremor [8].
In anesthetized rats, Berrino et al. [9] demonstrated the lack of effect of ICI
118.551 on the centrogenic cardiac arrhythmias elicited by icv injection of glutamate.
However, we noticed in a few experiments, that these beta 2 adrenergic blocking agent
could induce centrogenic cardiac arrhythmias, when administered icv alone. These
preliminary observations prompted us to study the effects of ICI 118.551 on the cardiac
excitability in a more detailed fashion.
We studied the influence of ICI 188.551 on the venticular fibrillation threshold
and excitability parameters, in isolated guinea pig hearts. For comparison, the effects of
beta 1 adrenergic blocking agent, metoprolol, and a quinidine-like compound, (+)
propranolol, were also studied. The actions of these drugs were investigated in hearts
from both nontreated and guanethidine pretreated animals. In these experimental setting,
guanethidine was used as a monoamine depletor [10].
Materials and methods
General procedures
The experiments were carried out in guinea pigs of both sexes, weighing
300400 g. The animals were sacrificed by decapitation, followed by a rapid
exsanguination. The thorax was rapidly opened, the heart removed and connected to the
cannula of a Langendorff perfusion device. The time period elapsed between the
removal of the heart and the connection to the perfusion device was less than one
minute, usually 40 seconds. The capacity of the organ bath was 10 ml. The heart was
perfused by a Krebs-Henseleit solution at a constant temperature (37 degree Celsius),
pressure and pH (7.4). This later parameter was maintained constant by varying the
proportion of O2/CO2 (approximately 95%/5%).
In preliminary experiments, it was shown that during a period of 40 min the
excitability parameters were unchanged. In the experiments reported here, following a
20 min equilibration period, the following parameters were recorded: heart rate,
duration of the ventricular monophasic action potential (MAPs), and the cardiac cycle
length. MAPs were recorded according to László [11]. The experiments were performed
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with either spontaneously beating or paced hearts. For recording of MAPs pacing or
delivery of extrastimuli, silver nonpolarizable needle electrodes were used.
In the paced heart, the heart was paced with a home made stimulator which
delivered the minimal current pulses necessary to avoid the occurrence of spontaneous
beats, namely a constant train with the following characteristics: 300 Hz frequency,
1 ms pulse width, 45 V intensity.
Determination of the diastolic threshold
The diastolic threshold, i.e. the minimal current intensity applied during the late
diastole which could elicit a ventricular extrasystole, was determined by using a home
made programmable stimulator delivering single pulses of 1.25 ms, variable intensities
(0100 mA) and constant frequency (50 Hz). The extrastimuli could be displaced in
time during the entire duration of the cardiac cycle by steps of 10 ms duration.
Determination of the refractory periods
A current of intensity of 2 times the diastolic threshold was used. Extrastimuli
were gradually displaced during the cardiac cycle length, starting with 30% of the
MAPs duration until the first ventricular extrasystole occurred. The time of occurrence
of this event following the beginning of the MAPs was considered as the functional
refractory period of the ventricle. Then, extrastimuli were delivered at the begining of
the MAPs and the corresponding time interval during which no extrasystoles could be
induced, was considered as the effective refractory period of the ventricle (as reported
to the beginning of the MAP).
Determination of vulnerable period and ventricular fibrillation threshold
The current intensity was increased 10 times and the delivered pulses were
displaced during the functional refractory period, until a ventricular fibrillation ensued.
The time interval measured between the beginning of functional refractory period and
the appearence of the ventricular fibrillation was termed vulnerable period. Then the
extrastimuli intensity was reduced until no ventricular fibrillation occurred any more.
The lowest current intensity which elicited ventricular fibrillation was termed
ventricular fibrillation threshold.
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Determination of maximal driving frequency
Finally, the extrastimulus was positioned as described for the determination of the
diastolic threshold and the frequency of stimulation was raised until an extrasystole
appeared. This was the maximal driving frequency, a parameter which indirectly
indicates the changes in heart excitability [12, 13].
Pharmacological procedures
Following the triplicate determination of these parameters, a 10-minute perfusion
of 0.31 mmol/l of ICI 118.551; 0.31 mmol/l of metoprolol or 0.31 mmol/l of (+)
propranolol (expressed as bases) was started. These doses were chosen following pilot
studies for testing the influence of various doses of metoprolol on the parameters of
cardiac excitability. The dose of 0.31 mmol/l of metoprolol was the dose being active in
all experiments. Equimolar dose (+) propranolol and ICI 118.551 were then chosen for
the present experiments.
During the perfusion period, MAPs were continuously recorded. At the end of the
perfusion, the changes in heart excitability were measured as previously described. In
addition, the coronary outflow was measured by collecting the fluid into calibrated
tubes.
The same procedures were applied in both spontaneously beating heart and paced
heart paradigms, either in untreated or guanethidine treated animals. Guanethidine
(25.2 mmol/kg) was injected intraperitoneally 24 hours before the start of the
experiment.
Drugs
The following drugs were used: ICI 118.551 hydrochloride (Zeneca); (+)
propranolol hydrochloride (Zeneca); metoprolol hydrochloride (Ciba-Geigy);
guanethidine sulphate (Sicomed, Romania). The doses of all drugs were expressed as
bases.
Statistical analysis
The effect of guanethidine and of each beta-blocker on the studied parameters
were analysed by t test. Thus, the unpaired t test was used to compare guanethidine
untreated versus guanethidine pretreated groups. The paired t test was used for
comparison within each group of the pre-versus post drug administration values [14].
Data are expressed as mean ±SE. Results are considered significant at p<0.05.
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Results
The effect of each beta-adrenergic blocker on spontaneously beating/paced hearts
in animals pretreated or non-pretreated with guanethidine will be separately described.
Effects of ICI 118.551 (Table I)
Spontaneously beating hearts in nonpretreated animals
ICI 118.551 perfusion elicited significant changes in all of the parameters
measured. With the exception of the heart rate which decreased (approximately by
25%), the rest of the parameters all increased. Note in particular the impressive increase
of the diastolic threshold to a value >100 mA (increase >2000%) and the ventricular
fibrillation threshold to a value >100 mA (increase >70%).
The other parameters also increased significantly: the MAPs duration by
approximately 35%, the functional and the effective refractory periods by
approximately 15% and 25%, respectively, the vulnerable period by approximately 15%
and the maximal driving frequency by approximately 10%.
Following a 7 min perfusion, 510 isolated ventricular premature beats were
noticed. In the following minutes, these rhythm disorders became more and more
frequent (up to 25), but they completely disappeared by the end of the perfusion.
Spontaneously beating hearts in guanethidine pretreated animals
In comparison with the untreated animals, guanethidine injected intraperitoneally
24 hours before the experiments, induced a large increase of the diastolic threshold
(approximately by 350%) and of the ventricular fibrillation threshold to values
>100 mA (>70%) and also a 20% increase of the effective refractory period. No
extrasystoles were recorded.
Following the perfusion of ICI 118.551, most measured parameters changed
significantly. Note a decrease of the diastolic threshold (approximately by 55%). The
vulnerable period duration and ventricular fibrillation threshold (>100 mA) were not
determinable in both pre- and post/- ICI 118.551 perfusion.
We also noticed a significant bradycardia (approximately by 15%), an increase of
the MAPs duration by 20%, an increase of the functional and effective refractory
periods (approximately by 20% and 10%, respectively) and a decrease of the maximal
driving frequency (approximately by 10%).
In only one experiment, did ICI 118.551 elicit a single extrasystole.
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Paced hearts in nonpretreated animals
Note the 60% increase of the diastolic threshold, the impressive augmentation to
a value higher than 100 mA of the ventricular fibrillation threshold (increase >200%)
and the increase of 10% of the maximal driving frequency.
It is noteworthy that during the perfusion period, a few ventricular extrasystoles
(35) occurred. We also observed decrease the coronary outflow (approximately by
60%) in paced hearts compared to spontaneously beating hearts.
Paced hearts in guanethidine pretreated animals
Compared to the untreated animals, guanethidine injected intraperitoneally 24
hours before the experiments, induced the following important changes in the control
animal: increase of the diastolic threshold (approximately by 280%), and increase of the
ventricular fibrillation threshold (approximately by 180%). Note also the decrease of the
MAPs duration (approximately by 30%) and decrease of the duration of the vulnerable
period (approximately by 70%).
Following the perfusion of ICI 118.551 in guanethidine treated animals, we
observed a significant decrease of the ventricular fibrillation threshold (approximately
by 15%) and a significant decrease of the maximal driving frequency (approximately by
10%).
Note the decrease of the coronary outflow (approximately by 20%) in paced
hearts compared to spontaneously beating hearts. No other changes occurred.
Effects of metoprolol (Table II)
Spontaneously beating hearts in nonpretreated animals
The perfusion of metoprolol induced a very significant increase of the functional
and effective refractory periods (approximately by 30% and 60%, respectively) and a
very significant elevation of the ventricular fibrillation threshold (approximately by
80%). Note also the significant bradycardia (approximately by 20%), and the increase
of the MAPs duration (approximately by 10%).
Metoprolol perfusion elicited a progressive increase of the number of premature
beats of ventricular origin (initially 35, finally 1015). They appeared with a 2 min
onset and drastically diminished at the end of perfusion.
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Spontaneously beating hearts in guanethidine treated animals
In comparison to the untreated control animals, guanethidine induced the
following changes: increase of 170% of the diastolic threshold and significant rise of the
fibrillation threshold to values >100 mA (increase of >130%). Note that the vulnerable
period duration was not determinable. Other changes consisted in significant decreases
of the MAPs duration (approximately by 30%) and functional refractory period
(approximately by 40%).
Before or following the perfusion of metoprolol, the ventricular fibrillation
threshold was so high that it could not be measured (>100 mA).
Following metoprolol perfusion, we also detected a significant bradycardia
(approximately by 15%), a significant increase of the Maps duration (approximately by
20%) and the effective refractory period (approximately by 10%) and a decrease of the
maximal driving frequency (approximately by 10%).
In guanethidine pretreated hearts, premature beats (25) were also observed.
Paced hearts in nonpretreated animals
No significant changes of the investigated parameters occurred. During the
metoprolol perfusion, some ventricular extrasystoles (24) were noticed. As expected,
the coronary outflow was lower for these paced hearts, as compared to the
spontaneously beating hearts (approximately by 10%).
Paced hearts in guanethidine pretreated animals
Compared to the untreated control animals, guanethidine induced the following
changes: an increase of the diastolic threshold (approximately by 27%) and an increase
of the ventricular fibrillation threshold (approximately by 90%). Note the decrease of
the MAPs duration (approximately by 30%) and the vulnerable period duration
(approximately by 80%).
Following the perfusion of the metoprolol in these pretreated animals, a
significant increase of the vulnerable period (approximately by 45%) and a significant
decrease of the maximal driving frequency (approximately by 10%) occurred.
Effects (+) of propranolol (Table III)
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Spontaneously beating hearts in nonpretreated animals
(+) Propranolol perfusion induced an important increase of the ventricular
fibrillation threshold (approximately by 110%). A reduction of the heart rate
(approximately by 15%) and an increase of the functional refractory period
(approximately by 20%) were also noted. Only some isolated extrasystoles (13) were
detected during the perfusion. They disappeared soon after the end of perfusion.
Spontaneously beating in guanethidine pretreated animals
As compared to the untreated control animals, guanethidine induced the following
changes: an increase of the diastolic threshold (approximately by 400%) and a
significant rise of the fibrillation threshold to values >100 mA (increase of >100%).
Note the bradycardia (approximately by 10%) and the fact that vulnerable period
duration was non determinable; no extrasystoles were recorded.
Either pre- or post (+) propranolol perfusion, the vulnerable period and the
ventricular fibrillation threshold (>100 mA) could not be measured, being too high for
the possibilities of our device to measure it.
Following the perfusion of (+) propranolol, we also detected the following
changes: bradycardia (approximately by 10%), increase of the MAPs duration by 25%
and 15% for the functional and effective refractory periods, respectively).
Paced hearts in nonpretreated animals
Note a significant increase of the ventricular fibrillation threshold of
approximately 100%. Other changes consisted in an increase of the functional and
effective refractory periods (approximately by 10%, respectively 15%) and of the
maximal driving frequency (approximately by 5%).
During the perfusion, a relatively large number of ventricular extrasystoles (1017)
was also noticed. As already described, the coronary outflow was lower for these paced
hearts, as compared to the spontaneously beating hearts (approximately by 10%).
Paced hearts in guanethidine treated animals
As compared to the untreated control animals, guanethidine induced changes
similar to those already described, namely a very significant increase (approximately by
200% of the ventricular fibrillation threshold). Other changes consisted in a decrease of
the MAPs duration of approximately by 25% and the vulnerable period duration of
50%.
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The perfusion of (+) propranolol in these pretreated animals failed to affect the
investigated parameters. In these paced hearts the extrasystoles [1520] failed to
disappear after the end of perfusion.
Discussion
During the perfusion of the ICI 118.551, premature ventricular beats were
frequently seen. It is noteworthy that the extrasystoles appeared not only under the
influence of ICI 118.551 perfusion, but also when two well-known antiarrhythmic drugs
metoprolol and (+) propranolol were perfused. These findings enabled us to think that
there is a nonspecific phenomenon, caused by the contact of foreign substances with the
heart. This effect is transient (this is an argument that the extrasystoles are of a
nonspecific character). Since a similar effect is not visible in guanethidine treated
animals, it may be concluded that it is due to a release of catecholamines in an active
form.
A surprising statement was that similar effects were seen with metoprolol and (+)
propranolol. Since guanethidine preadministration failed to affect the occurrence of
arrhythmias in these later cases, we suggest that they were probably due to mechanisms
differing from those invoved in the effect of ICI 118.551. Since both drugs have a
quinidine-like action [16] and since these types of drugs, when given in high doses,
frequently induce arrhythmias by a re-entry mechanism, it is tempting to ascribe the
extrasystoles seen during the perfusion period to this arrhytmogenic mechanism.
ICI 118.551 also induced a significant decrease of the heart rate both in controls
and guanethidine treated animals. This conclusion contrasts with the data of Bilski et al.
[5], who stated that in both controls and syrosingopine treated rats, ICI 118.551 failed
to induce any changes in the heart rate. This could be due to different experimental
conditions (different species, in vitro vs. in vivo experiments).
It is noteworthy that ICI 118.551 also exhibits a local anaesthetic and membrane
stabilising activity. It is not clear whether this property would contribute to the
antiarrhythmic effects of ICI 118.551 in coronary ligated rats [5].
All drugs investigated, namely metoprolol, (+) propranolol and ICI 118.551
elicited an increase of the ventricular fibrillation threshold in guanethidine pretreated
animals, as revealed by the experiments on paced hearts. This later effect of ICI
118.551 seems to be due to a depletion of some endogenous substance stores following
guanethidine pretreatment. The substances depleted by guanethidine, with an influence
of the profibrillatory effect of ICI 118.551 were certainly not catecholamines, since
these compounds possess essentially a threshold-lowering activity [1317]. Another
putative candidate is serotonin which is also depleted by guanethidine. But serotonin
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has also a fibrillation threshold reducing activity as shown by Szekeres and Papp [13]
and Cuparencu et al. (unpublished data). It is not excluded that the profibrillatory
activity of ICI 118.551 was unmasked following guanethidine pretreatment by depletion
of acetylcholine and gamma-aminobutyric acid (GABA) [10], exerting a contrary action
in intact animals.
It has to be mentioned that the spontaneously beating heart, the perfusion of ICI
118.551, besides the increases of the ventricular fibrillation threshold, also elicited an
increase of the refractory periods. However, there is probably no link between the
changes in the refractory periods and the changes in the fibrillation threshold since no
changes of the refractory periods were noticed in paced hearts, while the fibrillation
threshold could be modified. Other authors [5, 18] also noticed no link between changes
in cardiac excitability and those in fibrillation threshold. The fibrillation threshold
measures more the electrical inhomogeneity of the heart than its excitability. Thus, in
certain conditions, these parameters may change independently.
Metoprolol induced a very significant increase of the ventricular fibrillation
threshold, but only in spontaneously beating hearts. Note that metoprolol did not induce
a decrease of the fibrillation threshold in guanethidine pretreated animals, as did ICI
118.551, but rather a slight increase. The increase of the ventricular fibrillation
threshold could be secondary to the decrease of the animals heart rate [13]. Tosaki et al.
[19] also demonstrated that metoprolol exhibited an antifibrillatory effect, related to its
negative chronotropic activity. In spontaneously beating hearts, the ventricular
fibrillation threshold increased in parallel with the refractory periods and fibrillation
threshold. Guanethidine pretreatment failed to have any influence in paced hearts and
increased the bradycardic effects of (+) propranolol (in spontaneously beating hearts).
Metoprolol and (+) propranolol elicited ventricular extrasystoles, and this effect
was not influenced by guanethidine pretreatment. An exception was the absence of
extrasystoles in (+) propranolol perfused spontaneously beating hearts. Metoprolol and
(+) propranolol perfusion induced a very significant increase in the ventricular
fibrillation threshold, not influenced by guanethidine pretreatment. In spontaneously
beating hearts, the fibrillation threshold increases were accompanied by elevations of
the refractory periods.
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